女性保健市场 - 全球产业规模、份额、趋势、机会和预测，按药物、应用、地区和竞争细分，2019-2029F

2023 年全球女性医疗保健市场价值为 95.2 亿美元，预计到 2029 年预测期内将稳定增长，复合年增长率为 5.25%。妇女健康和福祉的日益重视等因素的综合作用。随着世界各地社会不断认识到优先考虑女性健康的重要性，女性医疗保健市场已成为创新和投资的焦点。

市场概况
预测期	2025-2029
2023 年市场规模	95.2亿美元
2029 年市场规模	123.3亿美元
2024-2029 年复合年增长率	5. 25%
成长最快的细分市场	普罗利亚
最大的市场	北美洲

技术进步在塑造女性医疗保健市场方面发挥了关键作用。从远距医疗和数位健康平台到穿戴式装置和个人化医疗，科技使女性能够掌控自己的健康和福祉。远端监控、虚拟咨询和健康应用程式越来越受欢迎，提供了方便易用的医疗保健解决方案。人们越来越重视预防性医疗保健，鼓励女性采取更健康的生活方式并定期接受检查。促进乳癌和子宫颈癌等疾病早期发现的措施在全球范围内受到关注。向预防性护理的转变旨在减轻慢性病的负担并改善整体健康结果。对妇女健康问题的认识不断提高，人们对医疗保健采取了更知情和积极主动的方法。月经健康、生育和更年期等问题现在正在被公开讨论，挑战社会禁忌，并有助于更全面地了解女性的医疗保健需求。

主要市场驱动因素

生活方式和营养的改变正在推动全球女性医疗保健市场。

可支配收入的增加正在推动全球女性医疗保健市场

主要市场挑战

健康差异

主要市场趋势

技术进步

细分市场洞察

药物见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球女性医疗保健市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依药物（EVISTA、XGEVA、Prolia、Mirena、Zometa、Reclast/Aclasta、Minastrin 24 Fe、NuvaRing、FORTEO、Premarin、ACTONEL、ORTHO TRI-CY LO (28)）
  • 依应用分类（荷尔蒙不孕症、停经后骨质疏鬆症、子宫内膜异位症、避孕药、更年期、多囊性卵巢症候群、其他）
  • 按地区
  • 按公司划分 (2023)
• 市场地图
  • 按药物分类
  • 按申请
  • 按地区

第 5 章：亚太地区女性医疗保健市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按申请
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 6 章：欧洲女性医疗保健市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按申请
  • 按国家/地区
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美女性医疗保健市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按申请
  • 按国家/地区
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第 8 章：南美洲女性医疗保健市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按申请
  • 按国家/地区
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲女性医疗保健市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 按药物分类
  • 按申请
  • 按国家/地区
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 10 章：市场动态

• 司机
• 挑战

第 11 章：市场趋势与发展

• 最近的发展
• 产品发布
• 併购

第 12 章：全球女性医疗保健市场：SWOT 分析

第 13 章：波特的五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 客户的力量
• 替代产品的威胁

第14章：竞争格局

• Bayer AG
• Cardinal Health
• Allergan plc.
• Merck & Co.
• Pfizer Inc.
• Amgen Inc.
• Agile Therapeutics Inc.
• Ferring Pharmaceuticals
• Mylan NV
• Lupin Limited
• Blairex Laboratories
• Apothecus Pharmaceutical

第 15 章：策略建议

第16章调查会社について・免责事项

Global Women Healthcare Market was valued at USD 9.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. The global women's healthcare market has witnessed significant growth and evolution in recent years, driven by a combination of factors such as increasing awareness, technological advancements, and a growing emphasis on women's health and well-being. As societies around the world continue to recognize the importance of prioritizing women's health, the women's healthcare market has become a focal point for innovation and investment.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 9.52 Billion
Market Size 2029	USD 12.33 Billion
CAGR 2024-2029	5. 25%
Fastest Growing Segment	Prolia
Largest Market	North America

Advances in technology have played a pivotal role in shaping the women's healthcare market. From telemedicine and digital health platforms to wearable devices and personalized medicine, technology has empowered women to take control of their health and well-being. Remote monitoring, virtual consultations, and health apps are becoming increasingly popular, providing convenient and accessible healthcare solutions. There is a growing emphasis on preventive healthcare, encouraging women to adopt healthier lifestyles and undergo regular screenings. Initiatives promoting early detection of diseases such as breast and cervical cancer have gained traction globally. The shift towards preventive care aims to reduce the burden of chronic conditions and improve overall health outcomes. Increased awareness of women's health issues has led to a more informed and proactive approach towards healthcare. Issues such as menstrual health, fertility, and menopause are now being discussed openly, challenging societal taboos and contributing to a more comprehensive understanding of women's healthcare needs.

Key Market Drivers

Changing Lifestyles and Nutrition are Driving the Global Women Healthcare Market.

The global women's healthcare market is undergoing a significant transformation, driven by changing lifestyles and a growing awareness of the critical role that nutrition plays in women's health. As societies evolve, so do the healthcare needs of women, prompting a surge in demand for innovative solutions and comprehensive care. The 21st century has witnessed a remarkable shift in the lifestyles of women worldwide. Factors such as increased urbanization, rising employment opportunities, and changing societal norms have led to alterations in daily routines and habits. While these changes bring new opportunities, they also present challenges to women's health. Sedentary lifestyles, stress, and inadequate sleep have become common features, contributing to various health issues. This shift has fueled a demand for healthcare solutions that address the specific needs of women in today's fast-paced world. Women are increasingly seeking healthcare services that provide holistic and personalized approaches to manage their health, taking into account their unique biological and lifestyle factors.

Nutrition is a cornerstone of overall health, and its significance is particularly pronounced in women's well-being. Proper nutrition is essential for the prevention of chronic diseases, the maintenance of a healthy weight, and the support of reproductive health. The global awareness of the intricate relationship between nutrition and women's health has led to a surge in demand for nutritional guidance, dietary supplements, and specialized healthcare products. The prevalence of conditions such as osteoporosis, anemia, and hormonal imbalances has led to a growing emphasis on nutrition as a preventive and therapeutic measure. Women are increasingly turning to healthcare providers and nutritionists for guidance on balanced diets, micronutrient supplementation, and lifestyle modifications that can positively impact their health.

The intersection of changing lifestyles and the focus on nutrition has created a dynamic landscape in the global women's healthcare market. Market players are responding to this shift by developing a wide array of products and services that cater to the unique healthcare needs of women. From fertility solutions and hormonal therapies to nutritionally fortified supplements and digital health platforms, the market is witnessing a surge in innovation. Moreover, the integration of technology, such as wearable devices and health apps, allows women to monitor and manage their health in real-time, empowering them to make informed decisions about their well-being. This convergence of healthcare and technology is reshaping the delivery of women's healthcare services, making them more accessible, personalized, and preventive.

Increasing Disposable Income is Driving the Global Women Healthcare Market

In recent years, a notable trend has emerged in the global healthcare sector - the surge in demand for women's healthcare services. This trend is closely linked to the increase in disposable income among women worldwide. As women gain greater financial independence, they are prioritizing their health and well-being, leading to a substantial growth in the global women's healthcare market. With higher disposable incomes, women have greater access to comprehensive reproductive health services. This includes advanced fertility treatments, family planning options, and prenatal care. As women are empowered to make choices regarding their reproductive health, the demand for specialized healthcare services in this domain has significantly increased.

Rising disposable incomes have enabled women to invest in preventive healthcare measures. Routine screenings, vaccinations, and health check-ups are now more affordable and accessible, leading to the early detection and prevention of various health conditions. This shift towards preventive care has positively impacted the overall well-being of women. The influx of disposable income has driven significant investments in research and development within the women's healthcare sector. This has resulted in technological advancements such as innovative diagnostic tools, minimally invasive surgical procedures, and personalized treatment plans. These developments enhance the overall quality of care for women. Women with higher disposable incomes are increasingly seeking holistic healthcare services that address both physical and mental well-being. This includes wellness programs, stress management, and mental health support tailored to the unique needs of women. As a result, the market for these services has expanded substantially. The aesthetic aspect of women's healthcare has also witnessed a surge in demand. Procedures such as cosmetic surgery, dermatological treatments, and other aesthetic interventions have become more accessible to women with increased disposable incomes. This reflects a broader societal shift towards self-care and personal grooming.

Key Market Challenges

Health Disparities

Health disparities among women remain a pervasive challenge in the global healthcare landscape. While advancements in medical science have led to significant improvements in women's health, a closer look reveals that not all women benefit equally. Disparities in healthcare access, treatment outcomes, and preventive care persist, posing a substantial hurdle to achieving comprehensive well-being for women worldwide. Health disparities refer to the differences in health outcomes and healthcare access among different populations. These differences are often influenced by various factors, including socioeconomic status, race, ethnicity, geographic location, education, and more. Unfortunately, these disparities are glaringly evident in the realm of women's healthcare, affecting everything from routine medical care to specialized treatments.

Key Market Trends

Technological Advancements

In recent years, the healthcare industry has experienced a paradigm shift, with technological advancements playing a pivotal role in transforming the landscape of women's healthcare. The Global Women's Healthcare Market has been witnessing a surge in innovation, fueled by breakthroughs in medical technology, data analytics, and telehealth solutions. Technological advancements have ushered in an era of precision medicine, allowing healthcare providers to tailor treatment plans based on an individual's genetic makeup, lifestyle, and environmental factors. In women's healthcare, this approach is particularly beneficial for conditions such as breast and ovarian cancers. Genetic testing and personalized treatment options empower women to make informed decisions about their health, leading to more effective and targeted interventions.

The rise of telehealth has been a game-changer in women's healthcare, providing convenient and accessible options for consultations, monitoring, and follow-up care. Telehealth platforms enable women to connect with healthcare professionals from the comfort of their homes, overcoming geographical barriers and improving the overall patient experience. Remote monitoring devices, such as wearable sensors, allow continuous tracking of vital signs and other health metrics, facilitating early detection of potential issues. Advances in fertility treatments and reproductive health technologies have significantly expanded options for women planning to start a family. Assisted reproductive technologies, including in vitro fertilization (IVF) and preimplantation genetic testing (PGT), have become more sophisticated and effective. Additionally, digital health tools and apps help women track their menstrual cycles, ovulation, and fertility windows, empowering them to take charge of their reproductive health. There has been a surge in digital health platforms dedicated to women's wellness, covering a broad spectrum of health concerns from pregnancy and maternal care to menopause and beyond. These platforms provide evidence-based information, personalized advice, and community support, fostering a holistic approach to women's health. From mental health apps to nutrition and fitness trackers, digital tools are empowering women to proactively manage their well-being. Artificial intelligence (AI) and machine learning are revolutionizing diagnostics in women's healthcare. These technologies enhance the accuracy and efficiency of medical imaging, such as mammography and ultrasound, leading to early detection of conditions like breast cancer. AI algorithms also assist healthcare professionals in analyzing vast amounts of patient data, enabling more precise diagnoses and treatment recommendations.

Segmental Insights

Drug Insights

Based on the category of drug, prolia emerged as the dominant player in the global market for Women Healthcare in 2023. Prolia, also known as denosumab, is a monoclonal antibody designed to treat osteoporosis in postmenopausal women. Developed by Amgen, this cutting-edge medication is a RANK ligand (RANKL) inhibitor, disrupting the biological pathway responsible for bone resorption. By inhibiting RANKL, Prolia effectively reduces the risk of fractures and enhances bone density. Osteoporosis, characterized by weakened bones and an increased susceptibility to fractures, particularly affects postmenopausal women due to hormonal changes that occur during menopause. Prolia has emerged as a frontrunner in osteoporosis treatment, offering a novel approach to managing bone health. The global prevalence of osteoporosis has led to an increased demand for effective treatments, and Prolia has positioned itself as a go-to solution. Prolia's success in the market can be attributed to its clinical efficacy and safety profile. Numerous clinical trials have demonstrated its ability to significantly increase bone mineral density and reduce the risk of fractures in postmenopausal women. Additionally, its mode of action, targeting RANKL, provides a unique advantage over traditional osteoporosis treatments.

The convenience of Prolia is another factor contributing to its dominance. Unlike oral medications that require daily or weekly administration, Prolia is administered through a subcutaneous injection once every six months. This not only enhances patient compliance but also ensures a consistent and controlled dosage. Prolia's success is not limited to a specific region, as it has achieved widespread acceptance globally. The drug has secured regulatory approvals from health authorities in various countries, attesting to its safety and efficacy. The expanding market reach of Prolia has positioned it as a frontrunner in the global women's healthcare market, capturing the attention of healthcare professionals, patients, and investors alike.

Regional Insights

North America emerged as the dominant region in the global Women Healthcare market in 2023, holding the largest market share in terms of value. North America has been at the forefront of adopting and developing cutting-edge medical technologies. The integration of technology in healthcare has resulted in improved diagnostics, personalized treatment plans, and enhanced patient care. The region's continuous investment in research and development has led to the creation of innovative solutions for various women's health issues. The United States and Canada boast advanced healthcare infrastructures that provide comprehensive services for women across all stages of life. Accessible healthcare facilities, well-equipped hospitals, and specialized clinics contribute to the region's dominance in offering a wide array of women's healthcare services.

Key Market Players

Bayer AG

Cardinal Health

Allergan plc.

Merck & Co.

Pfizer Inc.

Amgen Inc.

Agile Therapeutics Inc.

Ferring Pharmaceuticals

Mylan N.V.

Lupin Limited

Blairex Laboratories

Apothecus Pharmaceutical

Report Scope:

In this report, the Global Women Healthcare Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Women Healthcare Market, By Drug:

EVISTA XGEVA Prolia Mirena Zometa Reclast/Aclasta Minastrin 24 Fe NuvaRing FORTEO Premarin ACTONEL ORTHO TRI-CY LO (28)

Women Healthcare Market, By Application:

Hormonal Infertility Postmenopausal Osteoporosis Endometriosis Contraceptives Menopause Polycystic Ovary Syndrome Others

Women Healthcare Market, By Region:

North America
• United States
• Canada
• Mexico
Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
South America
• Brazil
• Argentina
• Colombia
Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Women Healthcare Market.

Available Customizations:

Global Women Healthcare market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Women Healthcare Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, ORTHO TRI-CY LO (28))
  • 4.2.2. By Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2023)
• 4.3. Market Map
  • 4.3.1. By Drug
  • 4.3.2. By Application
  • 4.3.3. By Region

5. Asia Pacific Women Healthcare Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug
  • 5.2.2. By Application
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Women Healthcare Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug
      • 5.3.1.2.2. By Application
  • 5.3.2. India Women Healthcare Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug
      • 5.3.2.2.2. By Application
  • 5.3.3. Australia Women Healthcare Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug
      • 5.3.3.2.2. By Application
  • 5.3.4. Japan Women Healthcare Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug
      • 5.3.4.2.2. By Application
  • 5.3.5. South Korea Women Healthcare Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug
      • 5.3.5.2.2. By Application

6. Europe Women Healthcare Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Women Healthcare Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Application
  • 6.3.2. Germany Women Healthcare Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Application
  • 6.3.3. Spain Women Healthcare Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Application
  • 6.3.4. Italy Women Healthcare Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug
      • 6.3.4.2.2. By Application
  • 6.3.5. United Kingdom Women Healthcare Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug
      • 6.3.5.2.2. By Application

7. North America Women Healthcare Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Women Healthcare Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Application
  • 7.3.2. Mexico Women Healthcare Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Application
  • 7.3.3. Canada Women Healthcare Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Application

8. South America Women Healthcare Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Women Healthcare Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Application
  • 8.3.2. Argentina Women Healthcare Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Application
  • 8.3.3. Colombia Women Healthcare Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Application

9. Middle East and Africa Women Healthcare Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Women Healthcare Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Application
  • 9.3.2. Saudi Arabia Women Healthcare Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Application
  • 9.3.3. UAE Women Healthcare Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Women Healthcare Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Bayer AG
  • 14.1.1. Company Snapshot
  • 14.1.2. Product & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Cardinal Health
• 14.3. Allergan plc.
• 14.4. Merck & Co.
• 14.5. Pfizer Inc.
• 14.6. Amgen Inc.
• 14.7. Agile Therapeutics Inc.
• 14.8. Ferring Pharmaceuticals
• 14.9. Mylan N.V.
• 14.10.Lupin Limited
• 14.11.Blairex Laboratories
• 14.12.Apothecus Pharmaceutical

15. Strategic Recommendations

16. About Us & Disclaimer